Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. / Jensen, Simon B K; Juhl, Christian R.; Janus, Charlotte; Lundgren, Julie R; Martinussen, Christoffer; Wiingaard, Christoffer; Knudsen, Cecilie; Frikke-Schmidt, Ruth; Stallknecht, Bente M; Holst, Jens J.; Madsbad, Sten; Torekov, Signe S.

In: Obesity, Vol. 31, No. 4, 2023, p. 977-989.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jensen, SBK, Juhl, CR, Janus, C, Lundgren, JR, Martinussen, C, Wiingaard, C, Knudsen, C, Frikke-Schmidt, R, Stallknecht, BM, Holst, JJ, Madsbad, S & Torekov, SS 2023, 'Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function', Obesity, vol. 31, no. 4, pp. 977-989. https://doi.org/10.1002/oby.23715

APA

Jensen, S. B. K., Juhl, C. R., Janus, C., Lundgren, J. R., Martinussen, C., Wiingaard, C., Knudsen, C., Frikke-Schmidt, R., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2023). Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity, 31(4), 977-989. https://doi.org/10.1002/oby.23715

Vancouver

Jensen SBK, Juhl CR, Janus C, Lundgren JR, Martinussen C, Wiingaard C et al. Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity. 2023;31(4):977-989. https://doi.org/10.1002/oby.23715

Author

Jensen, Simon B K ; Juhl, Christian R. ; Janus, Charlotte ; Lundgren, Julie R ; Martinussen, Christoffer ; Wiingaard, Christoffer ; Knudsen, Cecilie ; Frikke-Schmidt, Ruth ; Stallknecht, Bente M ; Holst, Jens J. ; Madsbad, Sten ; Torekov, Signe S. / Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. In: Obesity. 2023 ; Vol. 31, No. 4. pp. 977-989.

Bibtex

@article{db1ee20c8f6a42cb83688225094dc13d,

title = "Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function",

abstract = "OBJECTIVE: The aim of this study was to investigate glucose tolerance, glucagon response, and beta cell function during a 1-year maintenance period with either exercise, the glucagon-like peptide-1 receptor agonist liraglutide, or the combination after diet-induced weight loss.METHODS: In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m 2 ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo. Change in glucose and glucagon response to a 3-hour mixed meal test and disposition index, as a measure of beta cell function, were measured. RESULTS: A total of 195 participants were randomized. After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo. Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon. Exercise alone had similar postprandial glucose response, beta cell function, and glucagon response as placebo.CONCLUSIONS: Only the combination of exercise and liraglutide improved glucose tolerance, beta cell function, and glucagon responses after weight loss.",

keywords = "Adult, Humans, Liraglutide/pharmacology, Glucagon, Hypoglycemic Agents/therapeutic use, Weight Loss, Exercise, Glucose, Double-Blind Method, Blood Glucose, Diabetes Mellitus, Type 2/drug therapy",

author = "Jensen, {Simon B K} and Juhl, {Christian R.} and Charlotte Janus and Lundgren, {Julie R} and Christoffer Martinussen and Christoffer Wiingaard and Cecilie Knudsen and Ruth Frikke-Schmidt and Stallknecht, {Bente M} and Holst, {Jens J.} and Sten Madsbad and Torekov, {Signe S.}",

note = "{\textcopyright} 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.",

year = "2023",

doi = "10.1002/oby.23715",

language = "English",

volume = "31",

pages = "977--989",

journal = "Obesity",

issn = "1930-7381",

publisher = "Wiley-Blackwell",

number = "4",

}

RIS

TY - JOUR

T1 - Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function

AU - Jensen, Simon B K

AU - Juhl, Christian R.

AU - Janus, Charlotte

AU - Lundgren, Julie R

AU - Martinussen, Christoffer

AU - Wiingaard, Christoffer

AU - Knudsen, Cecilie

AU - Frikke-Schmidt, Ruth

AU - Stallknecht, Bente M

AU - Holst, Jens J.

AU - Madsbad, Sten

AU - Torekov, Signe S.

PY - 2023

Y1 - 2023

N2 - OBJECTIVE: The aim of this study was to investigate glucose tolerance, glucagon response, and beta cell function during a 1-year maintenance period with either exercise, the glucagon-like peptide-1 receptor agonist liraglutide, or the combination after diet-induced weight loss.METHODS: In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m 2 ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo. Change in glucose and glucagon response to a 3-hour mixed meal test and disposition index, as a measure of beta cell function, were measured. RESULTS: A total of 195 participants were randomized. After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo. Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon. Exercise alone had similar postprandial glucose response, beta cell function, and glucagon response as placebo.CONCLUSIONS: Only the combination of exercise and liraglutide improved glucose tolerance, beta cell function, and glucagon responses after weight loss.

AB - OBJECTIVE: The aim of this study was to investigate glucose tolerance, glucagon response, and beta cell function during a 1-year maintenance period with either exercise, the glucagon-like peptide-1 receptor agonist liraglutide, or the combination after diet-induced weight loss.METHODS: In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m 2 ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo. Change in glucose and glucagon response to a 3-hour mixed meal test and disposition index, as a measure of beta cell function, were measured. RESULTS: A total of 195 participants were randomized. After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo. Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon. Exercise alone had similar postprandial glucose response, beta cell function, and glucagon response as placebo.CONCLUSIONS: Only the combination of exercise and liraglutide improved glucose tolerance, beta cell function, and glucagon responses after weight loss.

KW - Adult

KW - Humans

KW - Liraglutide/pharmacology

KW - Glucagon

KW - Hypoglycemic Agents/therapeutic use

KW - Weight Loss

KW - Exercise

KW - Glucose

KW - Double-Blind Method

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2/drug therapy

U2 - 10.1002/oby.23715

DO - 10.1002/oby.23715

M3 - Journal article

C2 - 36942420

VL - 31

SP - 977

EP - 989

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 4

ER -

ID: 340806216